title: Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.
abstract: OBJECTIVE
  The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer
  
  
  METHODS
  Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated
  
  
  RESULTS
  The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score
  
  
  CONCLUSIONS
  Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.
authors.affiliation: Laboratory of Histology-Embryology, Democritus University of Thrace, 68 100, Alexandroupolis, Greece.
authors.forename: Maria
authors.initials: M
authors.lastname: Lambropoulou
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papadopoulos
authors.forename: Grigoris
authors.initials: G
authors.lastname: Tripsianis
authors.forename: George
authors.initials: G
authors.lastname: Alexiadis
authors.forename: Olga
authors.initials: O
authors.lastname: Pagonopoulou
authors.forename: Anastasia
authors.initials: A
authors.lastname: Kiziridou
authors.forename: Vassilios
authors.initials: V
authors.lastname: Liberis
authors.forename: Stylianos
authors.initials: S
authors.lastname: Kakolyris
authors.forename: Ekaterini
authors.initials: E
authors.lastname: Chatzaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D016019:Survival Analysis; D000077022:Survivin
chemical_list: D051546:Cyclooxygenase 2; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077022:Survivin; C107489:BIRC5 protein, human